Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Five Under 5: Top Oncology Videos for the Week of 8/24

August 31st 2025

The top 5 OncLive videos of the week cover insights in lung cancer, ovarian cancer, breast cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 8/24

August 30th 2025

The FDA has cleared a 3-month subcutaneous depot formulation of leuprolide mesylate in prostate cancer, gedatolisib NDA is under review in breast cancer, and more.

D3S-001 Receives FDA Breakthrough Therapy, Orphan Drug Designations in Select KRAS G12C-Mutant Solid Tumors

August 28th 2025

D3S-001 has received FDA breakthrough therapy and orphan drug designations in KRAS G12C-mutated NSCLC and CRC, respectively.

Experts Highlight Key Topics to Watch at the IASLC 2025 World Conference on Lung Cancer

August 28th 2025

Experts preview key abstracts to watch at the IASLC 2025 World Conference on Lung Cancer.

Perioperative Tislelizumab Wins EU Approval for Resectable NSCLC at High Risk of Recurrence

August 27th 2025

The European Commission approved neoadjuvant tislelizumab plus chemotherapy, followed by adjuvant tislelizumab, for resectable non–small cell lung cancer.

Ivonescimab Plus Chemo Boosts OS in Pretreated EGFR+ NSCLC

August 26th 2025

Ivonescimab plus chemotherapy improved overall survival in previously treated, advanced non–small cell lung cancer harboring EGFR mutations.

4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation

August 26th 2025

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Dr Abu Rous on the Timing of HER2 and MET Testing in NSCLC

August 22nd 2025

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Development Program for KB707 Will Prioritize Inhaled Formulation for NSCLC

August 22nd 2025

Krystal Biotech will prioritize the development of KB707 as an inhaled formulation for non–small cell lung cancer.

SCLC Data Drive Changes in First-Line Maintenance and Second-Line Care

August 21st 2025

Five experts gathered for the OncLive Peer Exchange to discuss SCLC data that continues to drive the evolving treatment paradigm.

AI Is Already Aiding Clinical Practice Across the Cancer Care Continuum

August 21st 2025

Clinicians spanning a spectrum of cancer subtypes discuss how they are currently using artificial intelligence in their daily practice.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

Dr Halmos on Selection Criteria for Adjuvant Therapy After Chemo/IO in NSCLC

August 19th 2025

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

NCCN Adds Zongertinib to Clinical Practice Guidelines in NSCLC

August 19th 2025

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.

Ifinatamab Deruxtecan Earns FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

August 18th 2025

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

August 18th 2025

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.